Iovance Biotherapeutics (0JDK) Share Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0JDK Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Iovance

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0JDK Stock 12 Month Forecast

Average Price Target

$6.50

▲(185.09% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $6.50 with a high forecast of $9.00 and a low forecast of $4.00. The average price target represents a 185.09% change from the last price of $2.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.969,2.509846153846154,3.050692307692308,3.5915384615384616,4.132384615384615,4.673230769230769,5.214076923076924,5.7549230769230775,6.295769230769231,6.836615384615385,7.377461538461539,7.9183076923076925,8.459153846153846,{"y":9,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.969,2.3175384615384615,2.6660769230769232,3.014615384615385,3.363153846153846,3.7116923076923074,4.0602307692307695,4.408769230769231,4.757307692307692,5.105846153846154,5.454384615384615,5.802923076923077,6.151461538461539,{"y":6.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.969,2.1252307692307695,2.2814615384615387,2.437692307692308,2.593923076923077,2.750153846153846,2.9063846153846153,3.0626153846153845,3.2188461538461537,3.375076923076923,3.531307692307692,3.687538461538461,3.8437692307692304,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.995,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.125,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.265,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.292,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.348,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.739,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.74,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.595,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.213,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.229,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.969,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$9.00

Average Price Target$6.50

Lowest Price Target$4.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joseph Pantginis

H.C. Wainwright

$20→$9

Buy

294.74%

Upside

Reiterated

11/06/25

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

Peter Lawson

Barclays

Buy

75.44%

Upside

Reiterated

11/04/25

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

Asthika Goonewardene

Truist Financial

―

Hold

―

Reiterated

11/04/25

Truist Financial Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

Geulah Livshits

Chardan Capital

$20

Buy

777.19%

Upside

Reiterated

08/08/25

Updating our model for 2Q25 financials and these updates shifts our PT to $20.

Yanan Zhu

Wells Fargo

$18→$14

Buy

514.04%

Upside

Reiterated

08/08/25

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)

Tyler Van Buren

TD Cowen

Buy

119.30%

Upside

Reiterated

08/07/25

Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives

Andrea Newkirk

Goldman Sachs

Sell

-56.14%

Downside

Downgraded

07/15/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Eli Lilly & Co (NYSE: LLY)

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

07/15/25

Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

David Dai

UBS

Hold

-12.28%

Downside

Downgraded

05/16/25

Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Salim Syed

Mizuho Securities

$30→$10

Buy

338.60%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), GH Research (NASDAQ: GHRS) and NewAmsterdam Pharma Company (NASDAQ: NAMS)

Colleen M. Kusy

Robert W. Baird

$20→$3

Hold

31.58%

Upside

Downgraded

05/09/25

Baird downgrades Iovanace Biotherapeutics (IOVA) to NeutralBaird analyst Colleen Kusy downgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Outperform to Neutral with a price target of $3.00 (from $20.00).

Kelsey Goodwin

Piper Sandler

―

Hold

―

Reiterated

04/01/25

Michael Yee

Jefferies

$23→$18

Buy

689.47%

Upside

Reiterated

03/13/25

Iovanace Biotherapeutics (IOVA) PT Lowered to $18 at JefferiesJefferies analyst Michael Yee lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $18.00 (from $23.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joseph Pantginis

H.C. Wainwright

$20→$9

Buy

294.74%

Upside

Reiterated

11/06/25

Iovance Biotherapeutics (IOVA) Gets a Buy from H.C. Wainwright

Peter Lawson

Barclays

Buy

75.44%

Upside

Reiterated

11/04/25

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)

Asthika Goonewardene

Truist Financial

―

Hold

―

Reiterated

11/04/25

Truist Financial Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

Geulah Livshits

Chardan Capital

$20

Buy

777.19%

Upside

Reiterated

08/08/25

Updating our model for 2Q25 financials and these updates shifts our PT to $20.

Yanan Zhu

Wells Fargo

$18→$14

Buy

514.04%

Upside

Reiterated

08/08/25

Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Iovance Biotherapeutics (IOVA)

Tyler Van Buren

TD Cowen

Buy

119.30%

Upside

Reiterated

08/07/25

Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives

Andrea Newkirk

Goldman Sachs

Sell

-56.14%

Downside

Downgraded

07/15/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA) and Eli Lilly & Co (NYSE: LLY)

Reni Benjamin

Citizens JMP

―

Hold

―

Reiterated

07/15/25

Citizens JMP Keeps Their Hold Rating on Iovance Biotherapeutics (IOVA)

David Dai

UBS

Hold

-12.28%

Downside

Downgraded

05/16/25

Cautious Outlook for Iovance Biotherapeutics Amid Amtagvi Sales Challenges

Salim Syed

Mizuho Securities

$30→$10

Buy

338.60%

Upside

Reiterated

05/09/25

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), GH Research (NASDAQ: GHRS) and NewAmsterdam Pharma Company (NASDAQ: NAMS)

Colleen M. Kusy

Robert W. Baird

$20→$3

Hold

31.58%

Upside

Downgraded

05/09/25

Kelsey Goodwin

Piper Sandler

―

Hold

―

Reiterated

04/01/25

Michael Yee

Jefferies

$23→$18

Buy

689.47%

Upside

Reiterated

03/13/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

1 Month

xxx

Success Rate

13/29 ratings generated profit

Average Return

-0.46%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 44.83% of your transactions generating a profit, with an average return of -0.46% per trade.

3 Months

xxx

Success Rate

9/17 ratings generated profit

Average Return

+7.25%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +7.25% per trade.

1 Year

Yanan ZhuWells Fargo

Success Rate

6/17 ratings generated profit

Average Return

-20.14%

reiterated a buy rating 3 months ago

Copying Yanan Zhu's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of -20.14% per trade.

2 Years

xxx

Success Rate

4/29 ratings generated profit

Average Return

-45.78%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.79% of your transactions generating a profit, with an average return of -45.78% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JDK Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JDK has received 6 Buy Ratings, 14 Hold Ratings, and 0 Sell Ratings. 0JDK average Analyst price target in the past 3 months is 6.50.

Each month's total comprises the sum of three months' worth of ratings.

0JDK Financial Forecast

0JDK Earnings Forecast

Next quarter’s earnings estimate for 0JDK is -$0.19 with a range of -$0.25 to -$0.13. The previous quarter’s EPS was -$0.25. 0JDK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0JDK has Preformed in-line its overall industry.

0JDK Sales Forecast

Next quarter’s sales forecast for 0JDK is $81.61M with a range of $74.27M to $91.90M. The previous quarter’s sales results were $67.45M. 0JDK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0JDK has Preformed in-line its overall industry.

0JDK Stock Forecast FAQ

What is GB:0JDK’s average 12-month price target, according to analysts?

Based on analyst ratings, Iovance Biotherapeutics’s 12-month average price target is 6.50.

What is GB:0JDK’s upside potential, based on the analysts’ average price target?

Iovance Biotherapeutics has 185.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Iovance Biotherapeutics a Buy, Sell or Hold?

Iovance Biotherapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is Iovance Biotherapeutics’s share price target?

The average share price target for Iovance Biotherapeutics is 6.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $9.00 ,and the lowest forecast is $4.00. The average share price target represents 185.09% Increase from the current price of $2.28.

What do analysts say about Iovance Biotherapeutics?

Iovance Biotherapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Iovance Biotherapeutics?

To buy shares of GB:0JDK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Iovance Biotherapeutics (0JDK) Share Forecast & Price Target

0JDK Analyst Ratings

0JDK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Iovance Biotherapeutics

0JDK Analyst Recommendation Trends

0JDK Financial Forecast

0JDK Earnings Forecast

0JDK Sales Forecast

0JDK Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts